Management of oxaliplatin-induced peripheral neuropathy

References

• AdelsbergerHQuasthoffSGrosskreutzJThe chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neuronsEuro J Pharmacol20004062532
   PubMed Web of Science ®Google Scholar
• AgafiteiRDSchneiderSIqbalSEffect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX) [abstract]J Clin Oncol2004223600
   Google Scholar
• AndreTBoniCMounedji-BoudiafLOxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancerN Engl J Med2004350234351 Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators15175436
   PubMed Web of Science ®Google Scholar
• ArmstrongCMCotaGCalcium block of Na+ channels and its effect on closing rateProc Natl Acad Sci U S A1999964154710097179
   PubMed Web of Science ®Google Scholar
• ArrickBANathanCFGlutathione metabolism as a determinant of therapeutic efficacy: a reviewCancer Res1984444224326380705
   PubMed Web of Science ®Google Scholar
• BrienzaSVignoudJItzhakiMOxaliplatin: global safety in 682 patients [abstract]Proc Am Soc Clin Oncol199514209
   Google Scholar
• CascinuSCatalanoVCordellaLNeuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo controlled trialJ Clin Oncol20021634788312177109
   PubMed Web of Science ®Google Scholar
• CavalettiGBogliunGZinconeANeuro- and ototoxicity of high dose carboplatin treatment in poor prognosis ovarian cancer patientsAnticancer Res19981837978029854499
   PubMed Web of Science ®Google Scholar
• CavalettiGTrediciGPetruccioliMGEffects of different schedules of oxaliplatin treatment on the peripheral nervous system of the ratEur J Cancer20013724576311720843
   PubMed Web of Science ®Google Scholar
• ContiJAKemenyNESaltzLBIrinotecan is an active agent in untreated patients with metastatic colorectal cancerJ Clin Oncol199614709158622015
   PubMed Web of Science ®Google Scholar
• de GramontACervantesAAndreTOPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancerJ Clin Oncol2004223525
   Google Scholar
• de GramontAFigerASeymourMLeucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerJ Clin Oncol20001829384710944126
   PubMed Web of Science ®Google Scholar
• EckelFSchmelzRAdelsbergerHPrevention of oxaliplatin neuropathy by carbamazepine. A pilot studyDtsch Med Wochenschr2003127788211797144
   PubMed Web of Science ®Google Scholar
• GamelinLBoisdron-CelleMDelvaRPrevention of oxaliplatin-related neurotoxicity by calcium magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancerClin Cancer Res20041040556115217938
   PubMed Web of Science ®Google Scholar
• GedlickaCScheithauerWSchüllBEffective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acidJ Clin Oncol20022033596112149316
   PubMed Web of Science ®Google Scholar
• GemlinEGamelinLBossiLClinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measuresSemin Oncol20025Suppl 152133
   Web of Science ®Google Scholar
• GoldbergRSargentDMortonRA randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancerJ Clin Oncol200422233014665611
   PubMed Web of Science ®Google Scholar
• GrahamMLockwoodGGreensladeDClinical pharmokinetics of oxaliplatin: a critical reviewClin Cancer Res2000612051810778943
   PubMed Web of Science ®Google Scholar
• GrolleauFGamelinLBoisdron-CelleMA possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channelsJ Neurophysiol2001852293711353042
   PubMed Web of Science ®Google Scholar
• GrotheyAOxaliplatin-safety profile: neurotoxicitySemin Oncol20034Suppl 1551314523789
   PubMed Web of Science ®Google Scholar
• GrotheyADeschlerBKroeningHPhase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC)Proc Am Soc Clin Oncol200221129a
   Google Scholar
• GrotheyAMcLeodHLGreenEMGlutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity [abstract]J Clin Oncol200523350915908661
   PubMed Web of Science ®Google Scholar
• HoffPPazdurRProgress in the development of novel treatments for colorectal cancerOncology200418705815214591
   PubMedGoogle Scholar
• HolmesJStankoJVarchenkoMComparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in the Wistar rat modelToxicol Sci1998463425110048138
   PubMed Web of Science ®Google Scholar
• HsiangYHLihouMGLiuLFArrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecinCancer Res1989495077822548710
   PubMed Web of Science ®Google Scholar
• JemalATiwariRCMurrayTCancer statistics, 2004CA Cancer J Clin200454814974761
   PubMed Web of Science ®Google Scholar
• LajerHDaugaardGCispaltin and hypomagnesemiaCancer Treat Rev199925475810212589
   PubMed Web of Science ®Google Scholar
• Maindrault-GoebelFde GramontALouvetCEvaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR)Ann Oncol20001114778311142489
   PubMed Web of Science ®Google Scholar
• MacdonaldRLKellyKMAntiepileptic drug mechanisms of actionEpilepsia199536Suppl 2S2128784210
   PubMed Web of Science ®Google Scholar
• MaestriAPasquale CerattiADCalandriCAcetyl-L-carnitine (ALCAR) in patients with chemotherapy-induced peripheral sensory neuropathyProc Am Soc Clin Oncol200221247b
   Google Scholar
• MarianiGGarroneOGranettoCOxaliplatin induced neuropathy: Could gabapentin be the answer?Proc Am Soc Clin Oncol200019609a
   Google Scholar
• MarshallJZakariAHwangJGinkgo Biloba (GB) extract as a neuroprotective agent in oxaliplatin (Ox)-induced neuropathy [abstract]J Clin Oncol2004223670
   Web of Science ®Google Scholar
• MeyerhardtJAMayerRJSystemic therapy for colorectal cancerN Engl J Med20053524768715689586
   PubMed Web of Science ®Google Scholar
• MidgleyRKerrDColorectal cancerLancet199935339199950460
   PubMed Web of Science ®Google Scholar
• NeijtJEngelholmSTuxenMExploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancerJ Clin Oncol20001830849210963636
   PubMed Web of Science ®Google Scholar
• PenzMKornekGVRadererMSubcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathyAnn Oncol200112421211332158
   PubMed Web of Science ®Google Scholar
• PetrelliNDouglasHOJrHerreraLThe modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study GroupJ Clin Oncol198971419262674331
   PubMed Web of Science ®Google Scholar
• PoonMAO'ConnellMJMoertelCGBiochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinomaJ Clin Oncol198971407182476530
   PubMed Web of Science ®Google Scholar
• SaifMWOral calcium ameliorating oxaliplatin-induced peripheral neuropathyJ Appl Res2004457682
   PubMedGoogle Scholar
• SaltzLCoxJBlankCIrinotecan plus fluoruracil and leucovorin for metastatic colorectal cancerN Engl J Med20003439051411006366
   PubMed Web of Science ®Google Scholar
• ScrenciDMcKeageMPlatinum neurotoxicity: clinical profiles, experimental models and neuroprotective approachesJ Inorg Biochem1999771051010626361
   PubMed Web of Science ®Google Scholar
• ShimadaYYoshinoMWakuiAPhase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancerJ Clin Oncol199311909138487053
   PubMed Web of Science ®Google Scholar
• TaiebSTrillet-LenoirVRambaudLLhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patientsCancer20029424344012015768
   PubMed Web of Science ®Google Scholar
• TournigandCAndreTAchilleEFOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyJ Clin Oncol2004222337
   Web of Science ®Google Scholar
• WilsonRLehkyTThomasRRAcute oxaliplatin-induced peripheral nerve hyperexcitabilityJ Clin Oncol20022017677411919233
   PubMed Web of Science ®Google Scholar
• WolmarkMWieandHSKueblerJPA phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract]J Clin Oncol2005233500
   Google Scholar
• WongGYMichalakJCSloanJAA phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: a North Central Cancer Treatment Group StudyProceedings of ASCO, 2005: May 14-172005Orlando, FL, USA8001
   Google Scholar
• WuFTakahashiMPegoraroEA new mutation in a family with cold-aggravated myotonia disrupts Na+ channel inactivationNeurology2001568788411294924
   PubMed Web of Science ®Google Scholar